Disruptive technology platforms from emerging companies hold great promise for exploiting innovation, but often face legitimacy hurdles due to their liability of newness. Nascent firms must learn new roles with limited precedent, and establish ties with an environment that may not fully...

Purpose – Building a bioeconomy requires efficient technology transfer and global linkages to exploit finite intellectual property exclusivity periods. Using a resource‐based view lens, this paper aims to assess the priorities, capabilities, and competitiveness of the emerging bioeconomy in...

Flawless product launches are critical success factors for biopharmaceutical companies due to increasing financial and technological risks. Industry benchmarking is widely used for managing biopharmaceutical product launch planning. However, while industry benchmarking may achieve operational...

Purpose: Using a dynamic capabilities lens, this paper aims to study the impact of genomics generally and gene therapy specifically on the rare disease sector of the biopharmaceutical industry. Design/methodology/approach: In this study, 24 genomics-based, rare disease-focused biopharma...

Purpose – Building a bioeconomy requires efficient technology transfer and global linkages to exploit finite intellectual property exclusivity periods. The purpose of this paper, using a resource‐based view lens, is to assess the priorities, capabilities, and competitiveness of the emerging...

Purpose – Using a values‐based leadership perspective, the paper aims to explore the Aeneid , Virgil's foundation epic of the Latin canon. Specifically, it aims to analyse the Aeneid in order to juxtapose the resonant leadership elements of vision, culture and values – and their...

This study explores how new ventures access advice to achieve high growth and sustainable performance. A relational model of three important themes — compliance (regulatory and legal governance), contacts (networks of suppliers, customers, investors), and content (strategic insights) —...

Leading biopharmaceutical firms need to dynamically optimize pipeline portfolios of internally and externally generated product candidates to ensure sustainable growth. This paper provides an empirical analysis of leading global biotechnology firms with respect to technology agglomeration...